Evogene (NASDAQ:EVGN), a leader in computational chemistry and generative AI for life sciences, announced the appointment of Dr. Olga Nissan as Vice President of Business Development, effective Jan. 1, 2026.
Dr. Nissan joins the Rehovot-based firm with over 15 years of leadership experience across the biotechnology, pharmaceutical, and AI-enabled drug discovery sectors.
Most recently, she served as CEO and Co-Founder of Protica Bio.
Her extensive resume also includes senior R&D and management roles at EcoPhage, BiomX, and Teva Pharmaceutical Industries.
She holds a PhD and completed postdoctoral research in biochemistry and proteomics at the prestigious Weizmann Institute of Science.
In her new role, Dr. Nissan will be tasked with accelerating Evogene’s commercial trajectory by securing strategic partnerships and expanding the reach of the company’s core technology, ChemPass AI.
The proprietary generative AI engine is designed to create novel, highly potent small molecules optimized for multiple parameters, significantly reducing the time and cost associated with traditional drug development.